Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Breast Cancer × abemaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 43 Neoplasm Metastasis 9 Neoplasms 7 Brain Neoplasms 7 Prostatic Neoplasms 6 Endometrial Neoplasms 6 Glioblastoma 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Meningioma 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Oligodendroglioma 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Hematologic Neoplasms 2 Glioma 2 Breast Neoplasms, Male 2 Breast Diseases 2 Breast Cancer Female 2 Venous Thromboembolism 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Unilateral Breast Neoplasms 1 Thyroid Neoplasms 1

Interventions

Fulvestrant 5 olaparib 4 Letrozole 4 Aromatase Inhibitors 3 Anastrozole 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 pyrotinib 2 eribulin 2 dalpiciclib 2 Goserelin 2 FCN-437c 2 Capecitabine 2 talazoparib 1 sonidegib 1 ribociclib 1 neratinib 1 liposomal doxorubicin 1 disitamab vedotin 1 ceralasertib 1 capivasertib 1 balixafortide 1 apatinib 1 abemaciclib 1 Vorinostat 1 Vinorelbine 1 Trastuzumab 1 Taxes 1 Tablets 1 Safety 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04227327 2025-07-29

HERMIONE-7

University of Milano Bicocca

Phase 2 Terminated

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡